QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gales, B. J Articles by Gales, M. A Search for Related Content PubMed PubMed Citation Articles by Gales, B. J Articles by Gales, M. A

DRUG INFORMATION ROUNDS

Pyridostigmine in the Treatment of Orthostatic Intolerance

Professor, Department of Pharmacy Practice, College of Pharmacy, Southwestern Oklahoma State University; Department of Pharmacy, Integris Baptist Medical Center, Oklahoma City, OK

Mark A Gales, PharmD BCPS

Professor, Department of Pharmacy Practice, College of Pharmacy, Southwestern Oklahoma State University; Department of Pharmacy, Integris Baptist Medical Center

Reprints: Dr. Barry J Gales, Department of Pharmacy, Integris Baptist Medical Center, 3300 Northwest Expressway, Oklahoma City, OK 73112, fax 405/951-8274, barry.gales{at}swosu.edu

OBJECTIVE: To review the efficacy of pyridostigmine bromide for the treatment of orthostatic intolerance.

DATA SOURCES: MEDLINE and International Pharmaceutical Abstracts were searched (1966-December 2006) using the terms pyridostigmine, acetylcholinesterase inhibitor, orthostatic intolerance, orthostatic hypotension, neurogenic orthostatic hypotension, postural tachycardia syndrome, tachycardia, and orthostatic tachycardia.

STUDY SELECTION AND DATA EXTRACTION: Pertinent English-language human clinical trials, case reports, and background material were evaluated for safety and efficacy data. The references of reviewed articles were reviewed and used to identify additional sources.

DATA SYNTHESIS: Pyridostigmine bromide has been associated with improved baroreceptor sensitivity and presents a novel approach to treatment of orthostatic intolerance. Four single-dose trials and a follow-up survey encompassing a total of 106 patients were identified. One open-label and one placebo-controlled single-dose trial in patients with neurogenic orthostatic hypotension (NOH) found statistically significant improvement in standing diastolic blood pressures (DBP). Absolute improvements in standing DBP were 3.7 and 6.4 mm Hg in the open-label and controlled trials, respectively. Long-term data consist of a single survey of patients receiving open-label pyridostigmine bromide. Twenty-nine percent of patients who initiated maintenance pyridostigmine bromide discontinued therapy. Concomitant NOH medications were taken by 75% of patients, and 85% of patients reported receiving benefit from pyridostigmine bromide. When evaluated for postural tachycardia syndrome, pyridostigmine bromide significantly reduced standing heart rate (10%). Pyridostigmine bromide significantly reduced symptom scores when compared with baseline but not placebo. The majority of patients included in these trials did not have supine hypertension.

CONCLUSIONS: Single doses of pyridostigmine bromide produced modest but statistically significant improvements in hemodynamic measurements. At this time, long-term data are insufficient to support recommending the routine use of pyridostigmine bromide for treatment of orthostatic intolerance.

Key Words: orthostatic hypotension, pyridostigmine

Published Online, February 6, 2007. www.theannals.com, DOI 10.1345/aph.1H458